These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

156 related articles for article (PubMed ID: 21358078)

  • 1. Risk-scoring system for predicting mucositis in patients of head and neck cancer receiving concurrent chemoradiotherapy [rssm-hn].
    Suresh AV; Varma PP; Sinha S; Deepika S; Raman R; Srinivasan M; Mandapal T; Reddy CO; Anand BB
    J Cancer Res Ther; 2010; 6(4):448-51. PubMed ID: 21358078
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Longitudinal evaluation of the oral mucositis weekly questionnaire-head and neck cancer, a patient-reported outcomes questionnaire.
    Epstein JB; Beaumont JL; Gwede CK; Murphy B; Garden AS; Meredith R; Le QT; Brizel D; Isitt J; Cella D
    Cancer; 2007 May; 109(9):1914-22. PubMed ID: 17377917
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Effect of topical morphine for mucositis-associated pain following concomitant chemoradiotherapy for head and neck carcinoma.
    Cerchietti LC; Navigante AH; Bonomi MR; Zaderajko MA; Menéndez PR; Pogany CE; Roth BM
    Cancer; 2002 Nov; 95(10):2230-6. PubMed ID: 12412178
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Phase II clinical trial of local use of GM-CSF for prevention and treatment of chemotherapy- and concomitant chemoradiotherapy-induced severe oral mucositis in advanced head and neck cancer patients: an evaluation of effectiveness, safety and costs.
    Mantovani G; Massa E; Astara G; Murgia V; Gramignano G; Lusso MR; Camboni P; Ferreli L; Mocci M; Perboni S; Mura L; Madeddu C; Macciò A
    Oncol Rep; 2003; 10(1):197-206. PubMed ID: 12469169
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Phase II study of palifermin and concurrent chemoradiation in head and neck squamous cell carcinoma.
    Brizel DM; Murphy BA; Rosenthal DI; Pandya KJ; Glück S; Brizel HE; Meredith RF; Berger D; Chen MG; Mendenhall W
    J Clin Oncol; 2008 May; 26(15):2489-96. PubMed ID: 18487568
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Validation of the Total Dysphagia Risk Score (TDRS) as a predictive measure for acute swallowing dysfunction induced by chemoradiotherapy for head and neck cancers.
    Koiwai K; Shikama N; Sasaki S; Shinoda A; Kadoya M
    Radiother Oncol; 2010 Oct; 97(1):132-5. PubMed ID: 20817288
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Concurrent chemotherapy and "concomitant boost" radiotherapy for unresectable head and neck cancer.
    Teh BS; Monga U; Thornby J; Gressot L; Parke RB; Donovan DT
    Am J Otolaryngol; 2000; 21(5):306-11. PubMed ID: 11032294
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Evaluating the supportive care costs of severe radiochemotherapy-induced mucositis and pharyngitis : results from a Northwestern University Costs of Cancer Program pilot study with head and neck and nonsmall cell lung cancer patients who received care at a county hospital, a Veterans Administration hospital, or a comprehensive cancer care center.
    Nonzee NJ; Dandade NA; Patel U; Markossian T; Agulnik M; Argiris A; Patel JD; Kern RC; Munshi HG; Calhoun EA; Bennett CL
    Cancer; 2008 Sep; 113(6):1446-52. PubMed ID: 18683883
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Gabapentin for the treatment of pain syndrome related to radiation-induced mucositis in patients with head and neck cancer treated with concurrent chemoradiotherapy.
    Bar Ad V; Weinstein G; Dutta PR; Dosoretz A; Chalian A; Both S; Quon H
    Cancer; 2010 Sep; 116(17):4206-13. PubMed ID: 20564146
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Intensive chemoradiotherapy as a primary treatment for organ preservation in patients with advanced cancer of the head and neck: efficacy, toxic effects, and limitations.
    Hanna E; Alexiou M; Morgan J; Badley J; Maddox AM; Penagaricano J; Fan CY; Breau R; Suen J
    Arch Otolaryngol Head Neck Surg; 2004 Jul; 130(7):861-7. PubMed ID: 15262764
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Hypofractionated accelerated radiotherapy with concurrent carboplatin for locally advanced squamous cell carcinoma of the head and neck.
    Chan AK; Sanghera P; Choo BA; McConkey C; Mehanna H; Parmar S; Pracy P; Glaholm J; Hartley A
    Clin Oncol (R Coll Radiol); 2011 Feb; 23(1):34-9. PubMed ID: 20863676
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Risk, outcomes, and costs of radiation-induced oral mucositis among patients with head-and-neck malignancies.
    Elting LS; Cooksley CD; Chambers MS; Garden AS
    Int J Radiat Oncol Biol Phys; 2007 Jul; 68(4):1110-20. PubMed ID: 17398022
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The M. D. Anderson symptom inventory-head and neck module, a patient-reported outcome instrument, accurately predicts the severity of radiation-induced mucositis.
    Rosenthal DI; Mendoza TR; Chambers MS; Burkett VS; Garden AS; Hessell AC; Lewin JS; Ang KK; Kies MS; Gning I; Wang XS; Cleeland CS
    Int J Radiat Oncol Biol Phys; 2008 Dec; 72(5):1355-61. PubMed ID: 18501527
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Incidence and costs of treatment-related complications among patients with advanced squamous cell carcinoma of the head and neck.
    Lang K; Sussman M; Friedman M; Su J; Kan HJ; Mauro D; Tafesse E; Menzin J
    Arch Otolaryngol Head Neck Surg; 2009 Jun; 135(6):582-8. PubMed ID: 19528407
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Radiotherapy with concomitant chemotherapy for head and neck cancer.
    Vokes EE; Awan AM; Weichselbaum RR
    Hematol Oncol Clin North Am; 1991 Aug; 5(4):753-67. PubMed ID: 1890065
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Acute-phase response reactants as objective biomarkers of radiation-induced mucositis in head and neck cancer.
    Mohammed FF; Poon I; Zhang L; Elliott L; Hodson ID; Sagar SM; Wright J
    Head Neck; 2012 Jul; 34(7):985-93. PubMed ID: 21953802
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Head and neck cancer patients treated with chemo-radiotherapy require individualized oncology nutrition.
    Kiyomoto D
    J Am Diet Assoc; 2007 Mar; 107(3):412-5. PubMed ID: 17324658
    [No Abstract]   [Full Text] [Related]  

  • 18. Therapeutic effect of recombinant human epidermal growth factor (RhEGF) on mucositis in patients undergoing radiotherapy, with or without chemotherapy, for head and neck cancer: a double-blind placebo-controlled prospective phase 2 multi-institutional clinical trial.
    Wu HG; Song SY; Kim YS; Oh YT; Lee CG; Keum KC; Ahn YC; Lee SW
    Cancer; 2009 Aug; 115(16):3699-708. PubMed ID: 19514089
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Adverse events associated with concurrent chemoradiation therapy in patients with head and neck cancer.
    Givens DJ; Karnell LH; Gupta AK; Clamon GH; Pagedar NA; Chang KE; Van Daele DJ; Funk GF
    Arch Otolaryngol Head Neck Surg; 2009 Dec; 135(12):1209-17. PubMed ID: 20026818
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Chemoradiotherapy for advanced inoperable head and neck cancer: A phase II study.
    Chougule PB; Akhtar MS; Akerley W; Ready N; Safran H; McRae R; Nigri P; Bellino J; Koness J; Radie-Keane K; Wanebo H
    Semin Radiat Oncol; 1999 Apr; 9(2 Suppl 1):58-63. PubMed ID: 10210541
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.